Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amcinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amcinonide SCHEMBL13026154 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL21051752 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL1649481 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL5488922 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL12396698 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL11422147 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL15975096 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL28971361 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL14884636 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL124165 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17500 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4744657-A1 | THERAPEUTIC AGENT FOR HUMAN GRAFT VERSUS HOST DISEASE AND COMBINATION THEREOF | National University Corporation Okayama University (JP) | 2026-05-20 | — | — | EP | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-3717017-B1 | COVALENT ANESTHETIC-POLYMER CONJUGATES FOR PROLONGED LOCAL ANESTHESIA | CHILDRENS MEDICAL CT CORP (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260027255-A1 | Cross-Linked Telechelic Polymer Compositions, Methods of Preparation Thereof, and Methods of Using Same | BETTY YU SKIN TECH ADVISORS LLC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4683679-A1 | METHOD FOR DIAGNOSING AND TREATING NIS-EXPRESSING CARCINOMAS AND METASTASES | NUSKE, Andreas (DE) | 2026-01-28 | — | — | EP | claimed |
| WO-1994013354-A1 | IN-TANDEM APPLICATOR PADS FOR THERAPEUTIC AGENTS | CREATIVE PRODUCTS RESOURCE, INC. (US) | 1994-06-23 | — | — | WO | claimed |
| US-5310545-A | Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter | EISEN DRORE | 1994-05-10 | — | — | US | claimed |
| EP-0484529-B1 | SKIN CREAM PREPARATION FOR EXTERNAL USE | HISAMITSU PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | claimed |
| US-5236906-A | Adrenocortical hormone and hyaluronic acid; skin diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-08-17 | — | — | US | claimed |
| US-5143661-A | Silicone-hardened pharmaceutical microcapsules | AMERICAN CYANAMID COMPANY (US) | 1992-09-01 | — | — | US | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| US-5061700-A | SOLVENTS FOR CORTICOSTEROIDS | Dow, Gordon Jay (US) | 1991-10-29 | — | — | US | claimed |
| WO-1991007169-A1 | GLYCERYL ACETATE OINTMENT VEHICLES | DOW GORDON JAY (US) | 1991-05-30 | — | — | WO | claimed |
| US-4788061-A | Extended occlusive treatment of skin disorders | SHORE RONALD N (US) | 1988-11-29 | — | — | US | claimed |
| US-4427670-A | CONTAINING CORTICOSTEROID, PHOSPHATIDE, AND BUTYLHYDROXYANISOLE, OR BUTYLHYDROXYTOLUENE | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1984-01-24 | — | — | US | claimed |